Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
about
Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancerHealth care costs: how do we decide value? When do we decide? How do we particularize the decisions?The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular subclassification study
P2860
Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trastuzumab for the treatment ...... a single technology appraisal.
@en
Trastuzumab for the treatment ...... a single technology appraisal.
@nl
type
label
Trastuzumab for the treatment ...... a single technology appraisal.
@en
Trastuzumab for the treatment ...... a single technology appraisal.
@nl
prefLabel
Trastuzumab for the treatment ...... a single technology appraisal.
@en
Trastuzumab for the treatment ...... a single technology appraisal.
@nl
P356
P1476
Trastuzumab for the treatment ...... a single technology appraisal.
@en
P2093
P356
10.3310/HTA13SUPPL1/01
P478
13 Suppl 1
P577
2009-06-01T00:00:00Z